Press Releases

Investors

E-mail Alerts

Aug 9, 2017

Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update

- VK5211 Phase 2 hip fracture study fully enrolled, data expected 4Q17

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Aug 2, 2017

Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017

Conference Call Scheduled for Wednesday, August 9 at 4:30 p.m. Eastern Time

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today...
Jul 12, 2017

Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture

Top-Line Results Expected in the Fourth Quarter

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Jul 6, 2017

Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Jun 14, 2017

Viking Therapeutics Announces $4.3 Million Registered Direct Offering

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...